Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Robert Brashear

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Neurology|February 15, 2015
Comment: Age effects on clinical trial results in Alzheimer dementiaH Robert Brashear
International Psychogeriatrics|September 30, 2005
Galantamine in the treatment of vascular dementiaH Robert Brashear
Clinical Pharmacology in Drug Development|June 20, 2018
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer DiseaseMing Lu, H Robert Brashear
The Journal of Clinical Psychiatry|February 8, 2007
Galantamine and QTc prolongationH Robert Brashear, J Michael Spivey
Cerebellum (London, England)|July 26, 2022
The Discovery of Anti-Yo (Anti-PCA1) Antibody in Patients with Paraneoplastic Cerebellar Degeneration: Opening a Window into Autoimmune Neurological DiseaseJohn E Greenlee, H Robert Brashear
The New England Journal of Medicine|April 12, 2014
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's diseaseStephen Salloway, Reisa Sperling, H Robert Brashear
Clinical Therapeutics|June 6, 2006
Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month studyFiona Dunbar, Young Zhu, H Robert Brashear
Current Alzheimer Research|August 22, 2018
Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension StudyStephen Salloway, Gad A Marshall, Ming Lu, et al.
Pharmaceutical Statistics|December 9, 2015
Continuous event monitoring via a Bayesian predictive approachJianing Di, Daniel Wang, H Robert Brashear, et al.
Current Medical Research and Opinion|October 22, 2005
Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteersQinying Zhao, Luc Janssens, Tom Verhaeghe, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Neurology|February 15, 2015
Comment: Age effects on clinical trial results in Alzheimer dementiaH Robert Brashear
International Psychogeriatrics|September 30, 2005
Galantamine in the treatment of vascular dementiaH Robert Brashear
Clinical Pharmacology in Drug Development|June 20, 2018
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer DiseaseMing Lu, H Robert Brashear
The Journal of Clinical Psychiatry|February 8, 2007
Galantamine and QTc prolongationH Robert Brashear, J Michael Spivey
Cerebellum (London, England)|July 26, 2022
The Discovery of Anti-Yo (Anti-PCA1) Antibody in Patients with Paraneoplastic Cerebellar Degeneration: Opening a Window into Autoimmune Neurological DiseaseJohn E Greenlee, H Robert Brashear
The New England Journal of Medicine|April 12, 2014
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's diseaseStephen Salloway, Reisa Sperling, H Robert Brashear
Clinical Therapeutics|June 6, 2006
Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month studyFiona Dunbar, Young Zhu, H Robert Brashear
Current Alzheimer Research|August 22, 2018
Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension StudyStephen Salloway, Gad A Marshall, Ming Lu, et al.
Pharmaceutical Statistics|December 9, 2015
Continuous event monitoring via a Bayesian predictive approachJianing Di, Daniel Wang, H Robert Brashear, et al.
Current Medical Research and Opinion|October 22, 2005
Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteersQinying Zhao, Luc Janssens, Tom Verhaeghe, et al.
Pageof 5